Summit Therapeutics Inc. · NASDAQ:SMMT
Summit Therapeutics — 42nd Annual J.P. Morgan Healthcare Conference 2024
21 slides from Summit Therapeutics's conference presentation, January 2024
Slide 1: 42nd Annual J.P. Morgan Healthcare Conference
42nd Annual J.P. Morgan Healthcare Conference Bob Duggan Dr. Maky Zanganeh Chairman & CEO CEO & President
Slide 2: Forward Looking Statement
Forward Looking Statement Any statements in this presentation about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s par
Slide 3: Summit Therapeutics Company Details
Summit Therapeutics Company Details Focus ONCOLOGY MISSION LEADERSHIP Partnership Akeso Inc. …Improve quality of life, increase Unmatched high-speed execution, Summit United States, Canada, potential duration of life, and resolve proven track record License Europe, Japan Territories serious medical
Slide 4: Partnership with An Aligned Mission
Partnership with An Aligned Mission Bringing ivonescimab to patients around the world Summit is actively recruiting two Phase III NSCLC clinical trials LEADING BIOPHARMA INNOVATOR1,2 COMPANY IN CHINA World’s first marketed PD-1 bispecific (cadonilimab)3 Michelle Xia, Ph.D. Co-Founder, Chairwoman, 3
Slide 5: Shaping the Path to Become a Commercial Entity
Shaping the Path to Become a Commercial Entity THE LANCET SITC Partnership Multiple First Phase II Data MOA First Consummated Meetings Patient In (Article) (Poster) Patient In Q1 2023 Q2 2023 Q3 2023 Q4 2023 Raised NSCLC EORTC-NCI-AACR Accepted $500M Phase II Data MOA IST Proposals (Poster) (Poster)
Slide 6: Ivonescimab: Mechanism of Action
Ivonescimab: Mechanism of Action
Slide 7: Designed to Potentially Improve the Balance of Anti-tumor Activity & Safety
Ivonescimab Designed to Potentially Improve the Balance of Anti-tumor Activity & Safety 1,2 Anti-VEGF First-in-Class* Cooperative Potential to Steer to Only Phase III PD-1/VEGF Binding Tumor vs. Healthy Tissue PD-1/VEGF Bispecific Simultaneous blocking Where there are In clinical Brings two validate
Slide 8: Cooperative Binding
Ivonescimab Cooperative Binding Greater Than the Sum of Its Parts Simultaneous blocking of PD-1 & VEGF 1,2,3 Increased Avidity in TME VEGF increases affinity to PD-1 by >18X4 PD-1 increases affinity to VEGF by >4X4 (in vitro) Enhanced Activity of T Cells VEGF dimer leads to potential interconnection
Slide 9: Clinical Data
Summit therapeutics - ae ae Clinical Data
Slide 10: 1L Adv/Metastatic Squamous NSCLC
1L Adv/Metastatic Squamous NSCLC 1,2,3 AK112-201 Cohort 1: Squamous only; Presentation Phase II Ivonescimab + Chemo exclusively for ivonescimab + chemo Phase II, N=63 Median follow up 21.0 months (DCO:10/10/2023) purposes of ORR† 67% evaluating the landscape for DCR† 95% ivonescimab mDOR† 12.8m AK11
Slide 11: 1L Adv/Metastatic Squamous NSCLC
1L Adv/Metastatic Squamous NSCLC 1,2,3 AK112-201 Cohort 1: Squamous only Presentation Phase II Ivonescimab + Chemo exclusively for ivonescimab + chemo Median follow up 21.0 months (DCO:10/10/2023) Phase II, N=63 purposes of evaluating the mOS Not Reached landscape for [22.5 – NE] ivonescimab 12m OS
Slide 12: 2L+ EGFR-TKI Progressors
2L+ EGFR-TKI Progressors 1,2,3 AK112-201 Cohort 2 (EGFR+) Presentation Phase II Ivonescimab + Chemo exclusively for ivonescimab + chemo Phase II, N=19 Median follow up 25.8 months (DCO:10/10/2023) purposes of evaluating the ORR† 68.4% [95% CI] [43 – 87] landscape for ivonescimab mDOR† 8.7m AK112-201
Slide 13: 2L+ EGFR-TKI Progressors
2L+ EGFR-TKI Progressors 1,2,3 AK112-201 Cohort 2 (EGFR+) Presentation Phase II Ivonescimab + Chemo exclusively for ivonescimab + chemo Median follow up 25.8 months (DCO:10/10/2023) Phase II, N=19 purposes of Overall Survival (OS) for EGFR-TKI evaluating the 22.5m landscape for mOS Progressors (N=19
Slide 14: Ivonescimab Phase II Safety Data in Key NSCLC Settings
Ivonescimab Phase II Safety Data in Key NSCLC Settings Ivonescimab Demonstrated a Tolerable Safety Profile Number (%) Top Treatment-Emergent Adverse Events 1L Squamous Grade >3 TRAE 28 (44.4) All TEAE 62 (98.4) Ivonescimab + TRAE leading to Anemia 39 (61.9) Chemotherapy discontinuation of 7 (11.1) i
Slide 15: Ivonescimab Opportunity
Ivonescimab Opportunity
Slide 16: There are 50+ Approved Indications for PD-(L)1 & VEGF Therapies
There are 50+ Approved Indications Glioblastoma for PD-(L)1 & VEGF Therapies Merkel Cell Carcinoma Basel Cell Carcinoma Nasopharyngeal Carcinoma Head & Neck Squamous Cell Cancer Esophageal Cancer Thyroid Cancer Classic Hodgkin Lymphoma Primary Mediastinal Large B-Cell Lymphoma Malignant Pleural Meso
Slide 17: Focusing On High Unmet Needs – Near Term
Focusing On High Unmet Needs – Near Term ~600,0001 Lung Cancer Patients in the US, Europe 5*, Japan ~40k ~80k Potential Potential Patients to Patients to Help Treat2 Help Treat3 * UK, Germany, France, Italy, Spain 1 American Cancer Society: www.cancer.org/cancer/types/lung-cancer/about/key-statistic
Slide 18: Ivonescimab Global Oncology Clinical Trials
Ivonescimab Global Oncology Clinical Trials Trial Indication Histology/Population Regimen Phase III EGFRm+ 2L+ Combo ivonescimab + NSCLC Advanced or Metastatic chemo vs. placebo + chemo NSCLC Squamous Combo ivonescimab + 1,600+ Patients 1L Metastatic chemo vs. pembro + chemo Treated with Ivonescimab
Slide 19: Ivonescimab: Expected 2024 Key Catalysts
Ivonescimab: Expected 2024 Key Catalysts
Slide 20: Ivonescimab Phase III Trials – Expected 2024 Short-Term Catalysts
Ivonescimab Phase III Trials – Expected 2024 Short-Term Catalysts Last Patient In H1 H2 AK112-303 AK112-301 Interim Analysis CDE Decision Randomized Expected* & Phase III Trial vs. Topline Data Head-to-Head vs. Same Subset Patient Pembrolizumab Pembrolizumab Population *NDA Filing by Akeso with the
Slide 21: Q&A
lUlpalaalis therapeutics is Q&A © eng enn
Summit Therapeutics — 42nd Annual J.P. Morgan Healthcare Conference 2024 on 6ix